Global obesity to reach 3.8 bn by 2050; India among worst affected: Study
The research, part of the Global Burden of Disease (GBD) Study 2021, found that nearly half the world's adults—over a billion men and a billion women aged 25 and above—were already overweight or obese in 2021.
India is projected to have the second-highest number of overweight and obese adults—218m men and 231m women—after China. (Representational image: iStock)
Vivek Mishra works as an Assistant Editor with Eastern Eye and has over 13 years of experience in journalism. His areas of interest include politics, international affairs, current events, and sports. With a background in newsroom operations and editorial planning, he has reported and edited stories on major national and global developments.
BY 2050, the number of overweight and obese people worldwide could reach 3.8 billion, with India accounting for over 440 million, a global study published in The Lancet journal has estimated.
India is projected to have the second-highest number of overweight and obese adults—218m men and 231m women—after China, while the United States, Brazil, and Nigeria follow, according to researchers, including those from the Indian Council of Medical Research.
The research, part of the Global Burden of Disease (GBD) Study 2021, found that nearly half the world's adults—over a billion men and a billion women aged 25 and above—were already overweight or obese in 2021. In India, this figure stood at nearly 180m, including 81m men and 98m women.
By 2050, the global number is projected to rise to 3.8 bn—1.8 bn men and 1.9 bn women—making up more than half of the world’s adult population, the authors said.
"While China, India, and the USA will continue to constitute a large proportion of the global population with overweight and obesity, the number in the sub-Saharan Africa super-region is forecasted to increase by 254.8 per cent," the researchers wrote.
For children, the study estimates that about 16m boys and over 14m girls in India aged 5-14 years could be overweight or obese by 2050, making India second only to China in this category. Among those aged 15-24, India is expected to have the highest number globally, with over 22m men and nearly 17m women affected.
Lead author Emmanuela Gakidou from the Institute for Health Metrics and Evaluation (IHME), University of Washington, said, "The unprecedented global epidemic of overweight and obesity is a profound tragedy and a monumental societal failure."
She said the study, described as the "most comprehensive global analysis to date," could help governments and public health authorities identify the populations most affected by obesity.
"This could help prioritise interventions and treatment for those in urgent need while focusing on prevention strategies for those predominantly overweight," she said.
The study comes after prime minister Narendra Modi highlighted the issue of obesity in his Mann Ki Baat radio address on February 23, calling for efforts to build a healthier nation.
Obesity—defined as a body mass index (BMI) over 30—is linked to various health risks, including metabolic and heart diseases, bone health issues, fertility problems, and an increased risk of cancer.
However, some experts have called for a reassessment of how obesity is measured. In January, a Lancet Commission report proposed a new approach beyond BMI, incorporating waist circumference and waist-to-hip ratio.
The report suggested new categories for diagnosing obesity—'clinical obesity' and 'pre-clinical obesity'—to provide a more accurate assessment of health risks.
Clinical obesity refers to a persistent condition due to obesity-related organ dysfunction, while pre-clinical obesity indicates increased health risks without an existing illness, the report explained.
Nine-time Grand Slam winner Monica Seles diagnosed with myasthenia gravis three years ago
The 51-year-old revealed her condition ahead of this month’s US Open to raise awareness
Disease causes muscle weakness and has no known cure
Former world number one Monica Seles has revealed she was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disease, three years ago. The 51-year-old, who won nine Grand Slam singles titles, went public ahead of the US Open to raise awareness of the condition, which causes muscle weakness and can affect multiple parts of the body.
Symptoms and diagnosis
Seles first began noticing symptoms around five years ago when she experienced double vision and struggled with coordination. “I would be playing [tennis] with some kids or family members, and I would miss a ball. I was like, ‘Yeah, I see two balls,’” she told the Associated Press. These symptoms eventually led to her diagnosis, which took time for her to come to terms with.
Living with the condition
The former tennis star described the impact of the disease on her daily life as “significant” and said it was initially difficult to discuss openly. Myasthenia gravis currently has no cure, but treatments can help manage its effects. By sharing her experience, Seles hopes to use her platform to educate others.
Career highlights
Seles rose to prominence as a teenager, winning her first Grand Slam at the 1990 French Open aged 16 and claiming eight majors by 19. Her career was interrupted in 1993 when she was stabbed by a spectator during a match in Hamburg. She returned to the sport and won one more Grand Slam before retiring in 2003, having spent 178 weeks as world number one and capturing 53 career titles.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
NexGen knee implant linked to high failure rates was used in over 10,000 UK operations.
Concerns flagged as early as 2014; withdrawn from UK market in 2022.
Hundreds of patients required corrective surgery, with costs running into millions.
Manufacturer Zimmer Biomet says patient safety is its “top priority” but will not cover revision costs up front.
Implant used despite early warnings
A knee replacement implant used in thousands of NHS operations was known to have a concerning failure rate eight years before it was withdrawn, a BBC File on 4 Investigates report has found.
The NexGen implant, made by US manufacturer Zimmer Biomet, was fitted in more than 10,000 patients between 2012 and 2022. Concerns were first raised by the National Joint Registry (NJR) in 2014, though insufficient data at the time made it difficult to draw firm conclusions.
The model in question included a modified “stemmed option tibial component” or “tibial tray”, lacking a layer of plastic found in earlier versions. It was marketed as a cheaper alternative for the NHS.
Patients left in pain and needing further surgery
Patients have reported severe complications after their implants slipped out of place, damaging bone and causing lasting mobility issues.
Debbie Booker, from Southampton, experienced severe pain a year after her 2016 surgery, eventually requiring a second knee replacement. She says the failed implant left her addicted to strong painkillers and caused long-term health problems, including the need for a hip replacement.
Another patient, “Diana”, had her implant fitted in 2021. When it slipped and began wearing away her shin bone, her consultant told her she was “standing on a broken leg”.
Surgeons raised repeated concerns
Irish knee surgeon Prof Eric Masterson reported a surge in corrective surgeries after switching to the NexGen implant in 2012. He says his concerns were dismissed by Zimmer Biomet representatives, a view echoed by NHS surgeons.
UK knee specialist Prof Leila Biant said she and colleagues raised warnings as early as 2017, but the company was slow to engage in evaluating affected patients.
Recall and high revision costs
By 2022, NJR data suggested patients with the NexGen implant were almost twice as likely to require corrective surgery compared with the average knee replacement. Zimmer Biomet recalled unused units from the UK market that year.
Studies have estimated failure rates for the tibial tray component between 6% and 19%. Hundreds of patients have undergone revision surgery, with more expected.
Each corrective procedure costs between £10,000 and £30,000, according to Southampton University’s Prof David Barrett, meaning the total bill is likely to run into millions. Zimmer Biomet has told sales staff it will not cover diagnostic, follow-up, or revision costs up front.
Official responses
Zimmer Biomet says it is “committed to the highest standards of patient safety, quality, and transparency” and acts in line with regulations when new data becomes available.
NHS England has confirmed it is “currently reviewing the case involving Zimmer Biomet NexGen knee implants”.
Keep ReadingShow less
A 34-year-old woman developed 43 aggressive skin cancer lesions triggered by HPV
HPV, a common STI, is now potentially linked to a deadly form of skin cancer
A 34-year-old woman developed 43 aggressive skin cancer lesions triggered by HPV
Researchers say this discovery could shift the approach to diagnosing and treating some skin cancers
Protection measures include vaccination, safe sex practices, and regular screening
Human papillomavirus (HPV), one of the most widespread sexually transmitted infections in the UK, is already associated with several serious cancers — cervical, throat, penile, anal, and head and neck cancers among them. Now, researchers in the US have raised concerns that it may also contribute to certain forms of skin cancer, especially in people with weakened immune systems.
Scientists from the National Institutes of Health (NIH) found signs of beta-HPV triggering squamous cell carcinoma in a young woman who had no major history of sun damage or other typical causes.
Case study reveals viral link to aggressive skin cancer
The patient, a 34-year-old woman, was referred to NIH after developing 43 lesions of squamous cell carcinoma on her face, legs, and hands. Despite undergoing surgery and immunotherapy, the cancer repeatedly returned.
Initial suspicions pointed to sun exposure and immune deficiency, but further investigation revealed that beta-HPV had inserted its genetic material into her skin cells’ DNA, enabling the virus to take over and fuel cancer growth.
Dr Andrea Lisco, a virologist and lead author of the study, said:
"This discovery could completely change how we think about the development, and consequently the treatment, of [skin cancer] in people who have a health condition that compromises immune function."
The woman was eventually diagnosed with a genetic immune disorder that left her T-cells – vital immune system fighters – impaired. After receiving a stem cell transplant to restore immune function, her skin cancer disappeared and other HPV-related symptoms, including growths on her tongue and skin, also resolved.
The findings were published in the New England Journal of Medicine. While they are preliminary, the research adds to the growing concern about HPV’s role in cancer development beyond the cervix or throat.
3 ways to reduce the risk of HPV-linked conditions
1. Get the HPV vaccine
The HPV vaccine is the most effective protection available. In the UK, it is routinely offered to all children aged 12 to 13, but those who missed it – particularly individuals at higher risk – can still get vaccinated. It is most beneficial before sexual activity begins, but remains helpful afterward.
2. Practise safer sex
Using condoms or dental dams during vaginal, anal and oral sex can significantly reduce the risk of transmission, although not entirely, as HPV spreads through skin-to-skin contact. Maintaining a mutually monogamous relationship can also help lower exposure risk.
3. Undergo regular screenings
Routine screening, especially for women, is crucial. Pap tests and HPV tests help detect abnormal changes in the cervix early, reducing the chance of progression to cervical cancer. Current guidelines recommend starting screening at age 21 and continuing up to age 65.
Keep ReadingShow less
The approach aims to reduce pain, shorten hospital stays, and improve patient outcomes
Glasgow-based CardioPrecision completes first clinical cases of robotic aortic valve replacement (AVR) through a small neck incision.
The procedure was carried out at Cleveland Clinic in the United States.
It uses the company’s CoreVista® Robot Enabling Platform to perform minimally invasive surgery.
The approach aims to reduce pain, shorten hospital stays, and improve patient outcomes.
Early results presented at major international conferences show clinical promise.
Glasgow medtech firm CardioPrecision has successfully performed the world’s first clinical cases of robot-assisted aortic valve replacement (AVR) using a small transcervical incision. This breakthrough could significantly reduce the need for traditional open-heart surgery.
The pioneering operations were carried out at the Cleveland Clinic in the United States, a centre globally recognised for its cardiovascular care. The procedures used CardioPrecision’s proprietary CoreVista® Robot Enabling Platform, offering a new route for accessing the heart valve via the neck rather than the chest.
Building on previous cadaver-based demonstrations of the AVATAR (Advanced Videoscopic Aortic Surgery by Transcervical Approach using Robot-assisted) concept, this marks the company’s transition from proof of concept to successful human application.
A move from concept to clinical reality
In 2023, CardioPrecision demonstrated its AVATAR technique in a series of cadaveric cases in Chicago. The procedures confirmed the feasibility of robot-assisted AVR using the CoreVista® platform. The company, spun out from the NHS with support from InnoScot Health, has since refined the technology for use in live patients.
This vision became a clinical reality in 2025, when a team led by Dr Marijan Koprivanac at Cleveland Clinic completed a small series of successful robot-assisted AVR procedures. The CoreVista® platform allowed surgeons to implant either conventional sutured or newer sutureless heart valves through a small neck incision.
Dr Koprivanac presented early data at the American Association for Thoracic Surgery and the International Society for Minimally Invasive Cardiothoracic Surgery meetings in May, noting significant advantages for patients.
He stated:
“Combining the artificial heart valve with this new surgical technology means patients should experience less pain and less time in the hospital. In fact, we believe this may be one of the least invasive surgical heart valve replacement options available.”
Scotland’s role in cardiac surgery innovation
The successful clinical deployment of the CoreVista® system marks a milestone for Scotland’s life sciences sector. CardioPrecision’s long-term vision has been to enable totally endoscopic heart surgery through a neck incision — an ambition now beginning to show tangible patient benefits.
Fraser Sutherland, Chief Medical Officer of CardioPrecision, said:
“The journey to realise our vision – to enable heart surgery to be performed through a small incision in the neck – began over a decade ago. Initially developed as a totally endoscopic procedure, we incorporated robot assistance to harness the dexterity of surgical robotics.”
Chief Executive Officer Ying Sutherland added:
“We are delighted to introduce this groundbreaking procedure to the medical community. Our unwavering commitment to advancing cardiovascular care has driven us to develop this innovative product, which we believe could revolutionise the approach to cardiac surgery.”
Support from InnoScot Health
CardioPrecision was originally formed through support from InnoScot Health, which works with NHS Scotland to bring new healthcare innovations to market. The organisation continues to play a role in the company’s governance and strategic direction.
Graham Watson, Executive Chair of InnoScot Health, commented:
“We congratulate CardioPrecision on its landmark breakthrough in robotic-assisted aortic valve replacement. It represents a vital step in producing improved outcomes through minimally invasive techniques. We are proud to continue supporting its world-leading capabilities.”
Over 7,000 chikungunya cases reported in southern China, mainly Guangdong province
Virus spread rapidly after an imported case was detected in Foshan on 8 July
Authorities enforcing hospital quarantine and door-to-door inspections
Chikungunya is mosquito-borne and not transmitted person to person
CDC issues travel alert; UK yet to release guidance
A mosquito-borne virus is spreading rapidly in China, with more than 7,000 people infected across at least 13 cities in Guangdong province. Authorities are introducing containment measures reminiscent of the Covid pandemic in an effort to stop the virus’s spread—even though chikungunya cannot be transmitted between people.
The outbreak began in Foshan, north of Hong Kong, where an imported case was confirmed on 8 July. The city has since recorded nearly 3,000 cases in just one week, according to Chinese media and international reporting.
What is chikungunya?
Chikungunya is a virus transmitted by mosquitoes. It is rarely fatal but can cause high fever, rash, fatigue, nausea, and intense joint pain that may last for months or even years. The World Health Organization describes it as a “debilitating” illness due to the prolonged joint pain it can cause.
The disease was first recorded in southern Tanzania in the 1950s. The name “chikungunya” comes from the Kimakonde language and translates as “that which bends up,” describing the posture of sufferers experiencing severe pain.
How does it spread?
Chikungunya is not contagious between people. It spreads only via mosquito bites. A mosquito becomes infected by biting a person who already has the virus, and then passes it on to others through subsequent bites.
What measures are being taken in China?
In Guangdong, authorities have mandated hospital quarantine for confirmed cases, requiring patients to remain under mosquito nets until they test negative.
Additional actions include:
Door-to-door inspections to eliminate mosquito breeding grounds
Penalties, including fines or charges, for residents who refuse access
Release of mosquito-eating fish into ponds
Use of large “elephant mosquitoes” whose larvae prey on disease-carrying species
Drone surveillance and widespread pesticide spraying
In one district, five households reportedly had their electricity cut off after failing to cooperate with inspections, according to The New York Times.
Is there a vaccine?
Yes. Two vaccines are approved in the United States:
IXCHIQ – a live-attenuated vaccine for adults aged 18 and over
VIMKUNYA – a virus-like particle vaccine for people aged 12 and older
The US CDC recommends the vaccine only for people travelling to outbreak zones.
Is chikungunya present in the UK or US?
Chikungunya is not currently circulating in the UK. In the US, most cases are linked to international travel. No locally acquired infections have been reported since 2019, though travel-related cases are rising. In 2024, 199 cases were reported in the US, and 46 have been recorded so far this year.
Where is the virus most commonly found?
The CDC lists Brazil, Colombia, India, Mexico, Nigeria, Pakistan, Thailand and the Philippines as higher-risk countries. Foshan has been placed under a Level 2 travel alert, with advice to be vaccinated before travel and to take mosquito precautions such as using insect repellent and wearing long clothing.
Pregnant women are advised to avoid travelling to affected areas.
What to expect next
Infections are expected to continue rising in southern China. On Monday, Hong Kong reported its first case—a 12-year-old boy who had recently travelled from mainland China.
Health authorities globally are monitoring the situation, although the UK government has not issued any formal warning so far.